News

Launched: Mae, a Maternal Health Tech Platform for Black Expectant Mothers

Last week Mae, a maternal health tech startup focused on providing critical resources to Black expectant mothers in the U.S. announced their soft-launch. ´The platform features a free birth planning tool that anyone can access, and free 15 minute consults with doulas for interested expectant mothers. The platform’s founder Maya Hardigan explains: “Mae is a digital health platform that elevates the standard of care for Black…

Pregna Launches CryoPop, a Carbon Dioxide (CO2) Based Innovative Cryotherapy Device to Fight Cervical Cancer

Pregna has recently announced the launch of its cryotherapy device CryoPop. The product was developed by Jhpiego with an objective of making treatment of cervical pre-cancerous lesions accessible to all. Pregna is the exclusive global commercialising partner for the device. “Cervical cancer is one of the most common and fatal forms of cancer in women worldwide, with about 85% of these deaths occurring in low and…

Runway Growth Capital Announces a Senior Secured Term Loan of $50M to Gynesonics for Their Intrauterine Fibroid Ablation System

Runway Growth Capital, a provider of growth loans to both venture and non-venture backed companies seeking an alternative to raising equity, announced today the closing of a senior secured term loan of $50 million to Gynesonics, a healthcare company focused on advancing women’s health by developing minimally invasive, incision-free, uterus-preserving, transcervical technologies for diagnostic and therapeutic applications. Gynesonics has developed and has received FDA clearance for…

BioAesthetics Announces a $5M Series A to Commercialize NACgraft, a Regenerative Nipple Graft for Breast Cancer Survivors

BioAesthetics Corporation today announced that it has doubled its initial Series A funding goal of $2.5 million, closed on Dec. 30, 2020, at $5 million to commercialize its NACgraft biologic matrix— a regenerative nipple graft for breast cancer survivors. BioAesthetics’ Series A was co-led by FemHealth Ventures and personally by BioAesthetics’ Director Sandra Coufal, MD, of Sibling Capital Ventures. BioAesthetics’ inaugural product, the NACgraft — for patients…

Echo Health Ventures Introduces New Innovation Alliance Bringing Together Three National Health Care Leaders to Collectively Invest in Transforming Health Care

Echo Health Ventures, a strategic collaboration of Cambia Health Solutions and Mosaic Health Solutions to invest in innovative health care companies, today announced the formation of the Echo Innovation Alliance, a powerful strategic investing engine that extends Echo’s proven investment model. Echo and USAble Corporation will collaborate through the newly formed Alliance to invest in transformative companies and drive broader market impact.…

Roche Launches Two Digital Pathology Image Analysis Algorithms for Precision Patient Diagnosis in Breast Cancer

Roche today announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine the best treatment strategy for each patient. The image analysis algorithms use artificial intelligence to support pathologists in making faster, more accurate patient diagnoses in breast cancer. The uPath image analysis algorithm suite…

The New York Academy of Medicine Launches New Initiative Focused on Maternal and Child Health

Building on its 173-year history of advancing medicine, science and public health, The New York Academy of Medicine (NYAM) has announced its convening of NYC and national experts to advance research and policy change for maternal and child health equity. NYAM recently launched a 13-member Women’s Health Research & Well-being Workgroup, and on January 12, 2021 will host a virtual Maternal and Child…

Sera Prognostics Partners With Anthem and HealthCore to Improve Outcomes for Preterm Babies

Sera Prognostics, a company focused on improving maternal and neonatal health through innovative precision biomarker approaches, together with leading health benefits company Anthem and its HealthCore subsidiary, an evidence generation company, have launched and started to enroll patients in a study to determine whether a test, along with clinical interventions, can lead to improved health for newborns and mothers. The primary objective…